SAN DIEGO, Aug. 31 /PRNewswire-FirstCall/ -- Marshall Edwards, Inc. (Nasdaq: MSHL), an
oncology company focused on the clinical development of novel
anti-cancer therapeutics, announced today that the Company's
management team will host a conference call with simultaneous
webcast on Wednesday, September 8,
2010 beginning at 5:00 p.m.
EDT. Daniel P. Gold, Ph.D.,
President and Chief Executive Officer, will present an update on
Marshall Edwards and its lead
programs, and Thomas M. Zech, Chief
Financial Officer, will provide an overview of the Company's fourth
quarter and fiscal year end 2010 financial results.
Conference Call and Webcast Information
To access the live call, please dial 866-543-6403 (domestic) or
617-213-8896 (international), passcode 35432389. A replay of the
call will be available approximately two hours after the conclusion
of the call and archived until September 15,
2010. To access the replay, please dial 888-286-8010
(domestic) or 617-801-6888 (international), passcode 43421051. The
conference call will also be webcast live and can be accessed at
www.marshalledwardsinc.com. Please connect several minutes prior to
the start of the webcast to ensure adequate time for any software
downloads that may be required.
About Marshall Edwards,
Inc.
Marshall Edwards, Inc. (NASDAQ:
MSHL) is a San Diego-based
oncology company focused on the clinical development of novel
anti-cancer therapeutics. These derive from an investigational
isoflavone technology platform, which has generated a number of
novel compounds characterized by direct targeting of tumor
metabolism. Specifically, these compounds are believed to target an
enzyme present in the cell membrane of cancer cells, thereby
inhibiting the production of pro-survival proteins within the cell.
Marshall Edwards has licensed rights
from Novogen Limited (ASX: NRT; NASDAQ: NVGN) for oncology drug
candidates Phenoxodiol, Triphendiol, NV-143 and NV-128. For more
information, please visit www.marshalledwardsinc.com.
SOURCE Marshall Edwards, Inc.
Copyright . 31 PR Newswire